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Abstract 
Patients face significant challenges when trying to understand the relative advantages and disadvantages of the variety of 
treatment options for serious diseases. This paper presents a description and evaluation of a novel visual decision aid designed to 
support shared decision making between patients and physicians. The objective of this research is empower patients to 
understand the differences among treatments that people like them chose, in terms of their resulting health outcomes. The visual 
depiction of the available options and the distributions of their relative desirability is called a decision space visualization (DSV). 
Prior research on DSVs shows that they have the potential to help shared patient-physician decision-making processes in 
situations where choices are not obvious and individual differences play a significant role in the decision. The DSV described 
here was achieved through three phases: developing requirements for the healthcare data that is filtered and displayed by the 
DSV, designing and developing the DSV application, and assessing the usability of the application in the context of a cancer 
diagnosis. The DSV detailed in this paper was found to be easy to understand, helpful, and promoted confidence in making 
treatment decisions.  
 
© 2014 The Authors. Published by Elsevier Ltd. 
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1. Introduction 
Medicine has matured to the point to where there are many possible treatment options for some of the more 
serious diseases. For example, patients with cancer may, in consultation with their physician, be asked to choose 
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from different types of radiation, chemotherapy, surgery, or combinations of these. Especially in the wake of getting 
the bad news of a diagnosis indicating a serious disease, it can be difficult for a patient to absorb the plusses and 
minuses of each of the many treatment types, assuming that they are discussed at all [1, 2]. Further, there are so 
many individual differences that it is difficult for patients to know what would likely be a good choice for them. 
But what if it is possible to show the ranges of outcomes for each possible treatment type for previous patients 
who have similar characteristics to the current patient? We have hypothesized that this kind of information will yield 
option awareness: the understanding of the available options and their relative desirability. A visual depiction of this 
information is called a decision space visualization (DSV), and we have been working to develop DSVs to empower 
patient decision making. Based on previous research with DSVs in other domains [3], they have the potential to help 
the shared patient-physician decision-making process in situations where the choice is not obvious and individual 
differences play a part in the decision. Edwards et al. [4] recommended using decision aids that include visual 
presentations of risk information; DSVs provide this functionality. 
We envision the patient sitting down with the physician to examine the data together, under the assumption that 
they plan to use a shared decision making model [5]. The physician will help select the relevant characteristics that 
will determine how similar the patient is to the previous patients whose records are represented in the data. Based on 
the degree of similarity desired, the physician will input the filtering parameters into the DSV and will judge 
whether sufficient numbers of data points appear in the visualization. Too few data points mean that it will be 
difficult to compare the current patient with the prior patients, and too many data points will make it difficult to see 
meaningful differences in the data. In accordance with Shneiderman’s principles for seeing visualizations change in 
real time, the physician will be able to quickly view when the “right” number of data points are displayed. Both 
determining the necessary degree of similarity, traded off with the acceptable number of data records populating the 
DSV, require human judgment. 
Once the physician has prepared the DSV, he or she will share it with the patient.  The physician will point out 
cases in which the outcomes are especially bad and good. Together, they will decide to drill down into individual 
data points to see more complete information about individual patients who appear to have anomalous outcomes.  
There have been some previous efforts to develop visualizations of health data to support decision making. Rind 
et al [6] examined many systems that visualize health informatics data, including several that enable users to see 
records from multiple similar patients simultaneously such as Lifelines2 [7], Similan [8], LifeFlow [9], Outflow 
[10], VisCareTrails [11], and PatternFinder [12]. While these systems enable filtering and exploration, none of them 
show treatment options in a manner that enables comparing the outcomes of one treatment versus another.  The 
Sepsis Treatment Enhanced through Electronic Protocolization (Steep) System [13] does recommend actions that 
could be taken to improve the diagnosis or treatment of a sepsis condition but does not include a visualization of the 
potential outcomes that may result from any of these actions.  The ARCHeS Outcomes Analyzer [14] depicts risks 
of death over time for different treatments, but does so in a way that shows series of point predictions expressed as 
probabilities.  Similarly, Hill et al. [15] show risk ratios as point predictions. In contrast, our research has focused on 
visualizing a range of outcomes for each option using a frequency distribution, since previous research has shown 
that even mathematically sophisticated users have a better understanding of frequency-based distributions rather 
than those based on probability [16].    
Perhaps the closest match to our research is a VA-funded project called VeteransLikeMe, which focuses on 
treatment decision support for atrial fibrillation. The VeteransLikeMe application mines Veterans’ Informatics, 
Information, and Computing Infrastructure (VINCI) data [17] to extract similar patients, treatments, and health 
outcomes. The research focus for VeteransLikeMe so far, however, has been on the natural language processing 
challenges and data mining algorithms rather than on visualizing the resulting DSV.  
The objective of this research is to create and evaluate the usefulness of a decision support application to help 
patients understand the differences among treatments that people like them chose in terms of their resulting health 
outcomes. To achieve the research objective, three phases were completed. In the first phase, we developed 
requirements for the data to be used by the DSV and chose the National Cancer Institute (NCI) Surveillance, 
Epidemiology and End Results (SEER) database, augmented with small amounts of synthetic data (described 
below). The second phase was the design and development of an interactive shared decision space visualization 
(DSV) to enable the patient and provider to determine the most satisfying treatment option based on treatment-
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outcomes for patients with similar attributes. The final phase was to assess the usability of the shared decision space 
application.  
2. Phase I: Data and user interaction requirements 
We developed requirements for historical datasets so that we could choose the most appropriate one to populate 
our prototype web-based Treatment Decision Space application.  We also considered the “ideal” data items that a 
dataset should contain in the case of a more fully-functional DSV application.  Key to populating DSVs is data that 
supports understanding the outcomes for each option: what happened when people with characteristics similar to 
those of the current patient elected to undergo Treatment A versus Treatment B. This simple statement has complex 
implications for data and user interaction requirements, which we examine below.  
Degree and type of similarity: in other words: how similar is “similar”?  For example, a patient’s age at first 
diagnosis is often important. But if a patient is 49 years old, should he ask to see only the outcomes for other 
patients who were exactly 49 at diagnosis? How about those who were 48 – 50? Or 45 – 50? The width of the range 
may vary based on the number of patients in the data set, because if only a handful of prior patients in the available 
database were exactly 49 years old at first diagnosis, asking only for 49-year-olds would likely provide insufficient 
comparative information for decision making. This constraint suggests a requirement for the patient and physician to 
be able to explore increasing and decreasing the range placed around the patient’s age.  
As another example, consider smoking history. Since smoking is a relevant factor in cancer prognoses, we 
imposed a requirement for providing a means to explore the data to show smokers versus non-smokers, defined as 
whether patients smoked at the time of the diagnosis. We recognize, however, that there are other approaches that 
should be considered that may impose more nuanced requirements.  For example, if patients do not currently smoke 
but had smoked earlier in their lives, it may be important to know how long they had smoked or how much per day 
the patient had smoked, and to be able to specify showing historical patients based on these factors. Similarly, if 
they had quit smoking by the time of diagnosis, it may be important to know how long before the diagnosis date 
they had quit.   
Obesity has issues that are similar to smoking. A person may not be obese at the time of a disease diagnosis, but 
if he or she was obese in the recent past, or was very obese at any time in the past, or was obese at any level for a 
long time until the recent past, any one of these factors may affect the ability of the patient to tolerate a current 
treatment. Thus, while we imposed a basic requirement to be able to show data of patients with a specified body 
mass index (BMI), more fine-grained requirements could be imposed to characterize obesity history.  
Whether a patient has some additional diseases or conditions (i.e. comorbidity) that may impact their ability to 
fight the disease of interest also needs consideration. Obviously, if the current patient who was just diagnosed with 
Disease B already has Disease A, the outcomes for him may be different from historical patients who only had 
Disease B. Once again, after the other condition(s) were identified for the relevant patients in the historical data, 
temporal issues could be addressed: how long before diagnosis of the disease of interest did the historical patients 
contract the comorbid disease or condition?  How severe is the comorbid disease or condition?  Besides the obvious 
phenotypical information, such as current BMI, even family disease history has a place in characterizing the recently 
diagnosed patient.  While we did not impose such a requirement for our proof-of-concept DSV application, we 
believe it would be ideal to have a requirement to filter patients by comorbid conditions. 
In summary, similarity is multidimensional. An individual historical patient could have a unique set of 
characteristics pertaining to comorbidity, obesity, behavioural patterns, and age at first diagnosis. The current patient 
may be similar to two different historical patients in different ways. There is an open research question regarding the 
most reasonable ways to judge degrees of similarity. 
Side effects: Part of depicting what happened when patients underwent a particular treatment involves showing 
whether they suffered side effects. We feel it is important to be able to show which historical patients were afflicted 
with which side effects, and thus imposed a requirement to be able to identify patients with the most common side 
effects.  A more nuanced requirement might also depict the severity of the side effects.  
Evaluative criteria: We required information about the outcomes of the selected treatments, because without 
this information, it is not possible to evaluate the options.  For our prototype DSV, we wrote a requirement to show 
“survival in number of months after diagnosis.”  An alternative requirement might call for creating a composite 
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“quality of life” score that takes into account both number of months of life after diagnosis plus the degree to which 
mild or severe side effects were present. Further, a requirement might be written so that patients are able to input 
their own weightings for such composite scoring criteria, to specify (for example) the importance of survival time 
versus minimal side effects.  
Staleness of data: The effectiveness of treatment options can change over time as techniques are refined. It’s 
possible that a treatment that took place more than 10 years ago was not as effective as the current execution of that 
treatment for a particular disease. An example is cranial radiation in children, which has been refined greatly in the 
last decade, resulting in better outcomes for more recent cases.  While we did not create such a requirement for our 
prototyping effort, it would be reasonable to require that data that shows treatments occurring greater than X years 
ago be removed from consideration (and, hence, visualization), with X being specified by the DSV’s user. 
Besides an option becoming more effective over time, new options are also devised that may not be fully 
represented in the historical data. Thus, the time window for when treatments took place is critical. There will 
always be a trade-off: the physician and patient are interested in seeing which treatments result in long-term survival 
with high quality of life, but historical cases showing a long post-treatment lifespan imply that their treatments 
occurred long ago. Thus it will be critical for the physician to know how similar the long-ago treatment is to the 
treatments that are being offered today for the relevant population. 
Given the constraints and considerations listed above, the following are types of data that could be of use, 
depending upon the illness or condition that is being treated. The general guidance is that data is relevant if it could 
be considered to represent a variable that interacts with courses of treatments to affect outcomes. For example, 
various characteristics of the patient, such as age and smoking habits, will affect overall health and treatment 
outcomes. Similarly, by taking into account the disease’s state at diagnosis, this data can help to characterize the 
underlying drivers of how the disease interacts with the person it is afflicting. Of course, not all of the example data 
items will be available in each case. 
 
Table 1. Proposed “ideal” data categories 
Data category Examples 
Phenotypic data Body mass index, age, gender 
Lifestyle characteristics Smoking, diet, exercise level, alcohol consumption 
Demographics Zip code of residence, education, socio-economic level 
Medical treatment demographics Zip code of the treatment location, experience of the medical team 
Disease demographics Stage at diagnosis, virulence, invasiveness, major site(s) of the disease 
Treatment characteristics Type of treatment selected, dates treatment began and ended 
Patient’s compliance capability Cognitive competence, education, co-presence of mental illness 
Co-morbidity Presence or absence of different kinds of other diseases 
Side effects Includes effects on quality of life; may be obtained via medical team’s notes 
Outcomes May be included in medical team’s notes; exact information needed 
depends on how outcomes are scored (e.g., survival time after diagnosis) 
Medical team’s notes on treatment 
history  
Includes treatment duration, number of courses of treatment, order of 
treatments if combinations of treatments are prescribed 
 
After comparing more than twenty datasets against our basic requirements, we elected to use the prostate cancer 
subset of the National Cancer Institute (NCI) Surveillance Epidemiology and End Results (SEER) public use dataset 
(http://seer.cancer.gov/). The SEER data contains limited information on demographics (age and ethnicity), 
treatments (surgery and radiation), and outcomes (mortality).  
While the SEER data was close to fulfilling our basic requirements, it fell short in several areas.  To fully assess 
our DSV concepts, we augmented the NCI SEER data with synthetic data. We added treatment options beyond 
surgery and radiation to include chemotherapy, hormonal therapy, none (active monitoring), and combination 
therapies. In addition, a physician on our team reviewed the literature and specified the likelihood of developing 
certain side effects, including anaemia, bowel dysfunction, decreased libido, and erectile dysfunction, after 
undergoing treatment.  This approach was necessary to allow us to assess during the usability testing phase the 
users’ understanding of the trade-offs of each treatment option. 
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Our hope is that, by describing the potential benefits of DSVs and the data that would be needed to populate 
them, the medical informatics community may move closer to a standard that would include the data that is most 
helpful to decision support.  
3. Phase II: Prototype development 
We developed the Treatment Decision Space to allow the patient and provider to select the relevant condition, 
enter demographic information, view treatment options and, most importantly, consider outcomes of similar patients 
who chose each treatment option. The application was implemented with a collection of javascript libraries such as 
Bootstrap (http://getbootstrap.com/) for rapid front-end interface development, Highcharts (http://  
www.highcharts.com/) for interactive charts, and the psMathStats (https://github.com/pseudosavant/psMathStats) 
for various math and statistics functions. All of these are the open-source libraries for non-commercial purposes. 
The reasons for use of the Bootstrap are consistency (the same result shown on different browsers) and 
responsiveness across platforms (desktop, tablet, or mobile), which reduced development time. The application was 
deployed on the Indiana University's Research Database Complex (RDC) web-servers. 
As shown in figure 1, the main visualization is a scatterplot where each dot represents a patient matched for age 
and ethnicity. Treatment options are listed along the x-axis and survival time along the y-axis. Dots towards the top 
of the plot represent patients who lived longer than dots towards the bottom of the plot. Numbers along the top of 
the plot represent the total number of patients who survived five years for each treatment as well as the percentage. 
Hovering over a dot provides information about the patient, including age, survival time, whether or not they 
smoked or if they had a family history of the condition, and also the side effects they experienced. 
Below the visualization is a set of filtering controls that allows users to further reduce the number of patients by 
showing only patients who smoked, had a high BMI, or had a family history of prostate cancer. Lastly, there is also 
the ability to highlight patients in the plot who experienced a particular side effect (figure 2). 
 
Figure 1. Overview of the Treatment Decision Space 
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4. Phase III: Usability study 
We conducted a usability study to assess the ease of use of the Treatment Decision Space. Participants were 
recruited from faculty, staff, and students on the campus of Indiana University. They were told for the purposes of 
the study to role-play a 45 year old black male diagnosed with Stage II prostate cancer. The interface was used on a 
15” MacBook Pro (with mouse) via a web browser.  
The test scenario was divided into two parts. During Part I, the first task was to enter the age, ethnicity, and stage 
of diagnosis for the patient they were role-playing. Upon seeing the initial decision space visualization (figure 1), 
participants were asked to determine which treatment option had the highest percentage of patients who survived at 
least five years and the number of patients who underwent each treatment. Participants then completed a worksheet 
in which they estimated the average survival time and the most common side effects associated with each treatment 
option. This task involved reading the overall values in the display as well as inspecting individual cases for each 
option. Based on those activities, they then identified the top two treatment options and provided an explanation of 
the trade-offs, if any, associated with those two treatments.  
In Part II, the participants filtered the data set to show only smokers, and they again identified the treatment 
option with the highest percentage survival in this revised decision space. Next, they were instructed to use the 
Figure 2. Treatment Decision Space filtered to show smokers experiencing weight loss 
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application to highlight cases with specific side effects (first bowel dysfunction and then weight loss) and also 
identify what other side effects co-occurred with bowel dysfunction. Participants then completed the same 
worksheet as Part I.  
As they completed the tasks, we collected metrics on speed and accuracy. At the end, they also completed 
questionnaires so that we could gather their subjective feedback on ease of use (System Usability Scale [18]) and 
open-ended answers about what they liked and disliked about the application, as well as ideas for how the 
application could be improved. 
5. Results 
Ten individuals participated in the study (six male, four female; three aged 18-25, three aged 26-25, two aged 46-
55, and two aged 56-65; seven white, two Asian, one black). Though the interface used prostate cancer as an 
example diagnosis (due to the availability of the data), female participants were included since the purpose of the 
test was to determine the clarity and usability of the interface, rather than its diagnostic utility for that specific 
condition. The usability sessions ranged from 19 to 44 minutes (M = 31.6 minutes), depending on the amount of 
time the participant chose to freely explore the interface and the number of questions or suggestions the participant 
discussed with the facilitator. Participants received a $10 gift card in exchange for their participation in the study. 
 In Part I, there were no difficulties with the first task, entering the patient’s demographic and diagnostic 
information into the interface. When asked to determine which treatment option had the highest percentage of 
patients surviving at least 60 months, five selected the correct answer (doing nothing – four patients with 100% 
survival rate) and five selected the second highest option (radiation – 35 patients with 94.3% survival rate). All 
participants accurately found the number of patients that selected each treatment option. The mean time to evaluate 
all seven treatment options and their side effects was 5 minutes and 38.14 seconds (SD = 2 minutes 14.48 seconds). 
Their visual estimates of the mean survival times roughly tracked the actual means in terms of rank, but not actual 
estimated value (Table 2). 
In Part II, after being informed that the person they were role-playing was a smoker, the filtered decision space 
showed two options with 100% survival rate after 60 months: hormonal therapy and doing nothing. Eight 
participants chose hormonal therapy, one chose doing nothing, and one chose surgery (82.1% survival rate). After 
using the filter tool to highlight specific side effects, all ten participants correctly identified surgery as the treatment 
option most associated with bowel dysfunction and correctly determined that erectile dysfunction was the most 
common co-occurring side effect with bowel dysfunction. Lastly, all participants correctly identified surgery plus 
radiation as the option with the most weight loss associated with it. However, only three participants recalled there 
was a tool specifically to filter side effects and instead manually inspected cases one by one in the interface until the 
facilitator reminded them of the tool for this. The mean time to evaluate all seven treatment options and their side 
effects in Part II was 4 minutes and 37.37 seconds (SD = 2 minutes 18.21 seconds). However, their visual estimates 
of the mean survival times tracked the actual means less accurately than in Part I (Table 2). 
 
Table 2. Estimates of mean survival months in Part I and Part II. Rank is in parentheses. 
Treatment option Phase I Actual 
(all patients) 
Phase I Estimate Phase II Actual 
(smoker subset) 
Phase II Estimate 
Chemotheraphy 60.82 (6) 60.70 (7) 57.89 (7) 60.50 (6) 
Chemo + Radiation 61.15 (5) 61.80 (6) 61.19 (6) 60.00 (7) 
Hormonal Therapy 60.16 (7) 62.70 (5) 67.88 (4) 63.50 (5) 
Do Nothing 70.00 (4) 66.67 (3) 71.00 (3) 67.70 (1) 
Radiation 70.66 (3) 65.90 (4) 67.43 (5) 64.30 (4) 
Surgery 75.06 (1) 66.90 (2) 74.09 (2) 66.60 (3) 
Surgery + Radiation 74.48 (2) 68.70 (1) 75.43 (1) 67.20 (2) 
  
The usability evaluator asked a series of questions about their experience using the application, which overall 
showed that participants had a positive experience (Table 3).  
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Table 3. Mean and standard deviation of usability survey answers (questions on a scale of 1 to 5) 
  
Question Mean SD 
I felt more confident selecting the top two treatment options after using the Treatment Decision 
Space website. 
4.2 0.92 
I found the website unhelpful when understanding my treatment options for Stage II prostate 
cancer. 
1.7 0.67 
The information presented on the website was easy to understand. 3.8 1.23 
Most people would require a lot of time to learn to use this website. 2.3 0.82 
In the future, I would like to use the Treatment Decision Space website when meeting with my 
provider to discuss treatment options. 
3.9 1.20 
I found the website unnecessarily complex. 1.9 0.57 
In the future I would like to use the Treatment Decision Space website when researching 
treatment options on my own. 
4.2 1.23 
I would need a technical person to interpret this website if I were to use it in the future 2.3 1.16 
 
Given a selection of 18 positive and negative terms about the application, participants were instructed to select 
the three that best describe it. The top five terms were informative, useful, advanced, clean, and appealing. 
Participants also listed their likes, dislikes, and ideas to improve the application, which are discussed further below.  
6. Discussion 
Overall, the prototype was found to be easy to understand, helpful, and promoted confidence in making treatment 
decisions. None of the users encountered problems so serious that they became stuck, requiring further instruction 
from facilitator. One feature some participants had to be reminded about was the control to filter the results for 
specific side effects. Participants were directly instructed to use the tool first when looking for the treatment option 
most associated with bowel dysfunction. A few moments later, when asked to find the treatment option most 
associated with weight loss, only three participants recalled the existence of the tool and used it, while the rest 
manually inspected cases in the interface, one by one. After 30 seconds, the facilitator reminded them of the filter 
tool, which they successfully used to answer the question. 
Participants were reluctant to choose “Do nothing” as a treatment option, even though it initially showed the 
highest percentage of survival in this particular data set, with five of the ten participants choosing the treatment 
option with the second highest survival rate instead. A comparable effect was seen in prior experiments with 
simulated emergency management decisions using a similar decision aid that showed distributions of outcomes for a 
variety of resource allocation choices, such as sending different numbers of fire trucks to a fire [3]. For some 
scenarios, the decision aid recommended doing nothing as the best option, generally in cases where the magnitude 
of the event exceeded the maximum number of resources that could be allocated, and therefore would fail no matter 
what. Expending any resources would simply be wasteful, not only in terms of the cost of using those resources, but 
also in putting the city at risk by having too few resources in reserve for the next emergency event. Despite being 
trained for these cases, participants would frequently select some other option despite the display clearly indicating 
it was a worse choice [19]. This may be related to a bias toward unrealistic optimism, in which decision makers 
intuitively feel that the current situation is unique and an external recommendation (in this case, the decision aid) 
does not apply [20]. To counteract this bias, it may help to design the decision aid to give the patient more perceived 
ownership of the recommendation, making the recommendation less external and possibly less objectionable. This 
might be achieved by providing more user control in selecting the input data and diagnostic parameters, in 
conjunction with the expertise of the clinician, so that the user feels more in control of where the recommendation 
comes from. 
Participants noted in the open-ended questions after the study that it was difficult to accurately estimate a mean 
value from a bar full of dots. If it was important to know the mean value, they stated that system should simply 
display it for them. However, an explicit indicator of the mean was omitted due to its anchoring effect; it was 
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important to emphasize the distribution of outcomes for each treatment option. Decision aids comparing multiple 
options often display a mean score or probability of success, which reduces visual complexity but conceals the real 
complexity inside the shape of outcomes for each option [21]. Prior studies using decision-space visualizations used 
boxplots indicating the median, minimum, maximum, and 25th and 75th percentiles. Controls in the interface allowed 
users to weight each of those five anchors according to different strategies, such as favoring the best-case scenario 
(emphasize the maximum) or a normal balance (emphasize the median). This was intended to draw the user’s 
attention to the amount and shape of variation in outcomes, rather than overemphasize one specific optimal value. 
Related to this point, participants made these estimates of the mean more quickly in Part II than in Part I, suggesting 
a learning effect, but made less accurate estimates. This may be due to the increased difficulty of estimating a mean 
from significantly fewer outcomes in the display for each treatment option. Ultimately, the decision of which visual 
affordances to include in the distributions will depend greatly on the type of dialogue expected between patient and 
clinician. 
Significant among the features liked by participants was the filtering functionality, specifically noted by five of 
the ten participants. They appreciated how the information could be individualized for each patient using the system. 
Some participants did not like the use of round dots for living patients and diamonds for deceased patients, finding 
them hard to differentiate, especially when many points happened to cluster together. Some participants also 
wondered what information was being concealed by the visualization, that the system “makes too many assumptions 
about the individual cases [and] may be more complex than it seems” and “not knowing the background for the 
people that died.” One participant wished to know the source of the data and/or citations for the evidence behind the 
information in the display. Some participants suggested additional pieces of information that would be useful, such 
as tables or pop-ups describing the terminology of treatments and side effects (e.g. defining fatigue, erectile 
dysfunction, etc.).  
7. Conclusions 
We feel that a decision support application, such as the Treatment Decision Space, has the potential to help a 
patient struggling to make a treatment decision when there are two or more options before the patient, each with its 
own pros and cons, and when individual differences matter. Specific conditions that could benefit from such a 
decision support application include prostate cancer, breast cancer, hypertension, and atrial fibrillation. In addition, 
it could also apply to someone trying to decide whether or not to undergo screening for a condition. 
The sample size was low but not atypical for a first-round usability study on a new application. Additional 
participants would most likely not add many additional insights not seen with the first ten participants. The fact that 
it was a male-specific condition used as the example case (prostate cancer) may have led female participants to 
approach the interface differently than male participants, so a future replication using a female-specific or gender-
neutral condition may provide additional insights into how patients might use this application. 
In this effort we were able to take the first step of assessing the usability of the Treatment Decision Space. The 
next logical steps would be to improve the prototype based on the findings from the usability study. Participants 
made several suggestions worth further exploration, such as providing a ranking system based on the user’s choices 
and preferences. We introduced a ranking feature to the emergency management-based decision space visualization 
in a prior study [22]. Following this round of improvement to the application, we plan to obtain a set of de-identified 
medical records, and to assess its usefulness using real patients and healthcare providers. Plans are currently 
underway to replicate this study with clinicians playing themselves, in the same scenario, to better understand the 
use of the application from the other side of the doctor-patient shared decision-making process. 
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